GW Pharmaceuticals PLC- (NASDAQ:GWPH) Insider Sells $71,638.56 in Stock

Share on StockTwits

GW Pharmaceuticals PLC- (NASDAQ:GWPH) insider Douglas B. Snyder sold 4,968 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $14.42, for a total transaction of $71,638.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of NASDAQ GWPH opened at $172.45 on Friday. GW Pharmaceuticals PLC- has a 1 year low of $90.14 and a 1 year high of $196.00. The stock’s 50 day moving average price is $174.62. The firm has a market capitalization of $5.20 billion, a price-to-earnings ratio of -16.33 and a beta of 2.32. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.19 and a current ratio of 7.81.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.48) by $0.80. The company had revenue of $39.20 million for the quarter, compared to analyst estimates of $12.32 million. GW Pharmaceuticals PLC- had a negative net margin of 458.79% and a negative return on equity of 45.75%. GW Pharmaceuticals PLC-‘s revenue for the quarter was up 1189.5% on a year-over-year basis. During the same quarter last year, the business earned ($3.12) EPS. Analysts anticipate that GW Pharmaceuticals PLC- will post -4.76 EPS for the current fiscal year.

A number of analysts recently issued reports on the stock. BidaskClub lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Oppenheimer decreased their target price on shares of 2U from $83.00 to $67.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 8th. Guggenheim restated a “buy” rating and set a $222.00 target price (up previously from $186.00) on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, May 7th. Morgan Stanley restated a “buy” rating on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, April 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of LYFT from $82.00 to $86.00 in a research report on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company’s stock. GW Pharmaceuticals PLC- has an average rating of “Buy” and an average price target of $205.40.

Several institutional investors and hedge funds have recently made changes to their positions in GWPH. Horan Capital Advisors LLC. acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $25,000. Exane Derivatives acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $28,000. TCG Advisors LP acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $29,000. Institutional & Family Asset Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $31,000. Finally, Paragon Capital Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $34,000. Institutional investors own 78.91% of the company’s stock.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Story: Market Capitalization – What it Means for Investors

Insider Buying and Selling by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Slack  Earns Neutral Rating from Analysts at Credit Suisse Group
Slack Earns Neutral Rating from Analysts at Credit Suisse Group
Slack  Coverage Initiated by Analysts at Morgan Stanley
Slack Coverage Initiated by Analysts at Morgan Stanley
Solaris Oilfield Infrastructure  Coverage Initiated by Analysts at Citigroup
Solaris Oilfield Infrastructure Coverage Initiated by Analysts at Citigroup
Tanger Factory Outlet Centers  Upgraded to “Hold” at Zacks Investment Research
Tanger Factory Outlet Centers Upgraded to “Hold” at Zacks Investment Research
Sterling Bancorp  Coverage Initiated at B. Riley
Sterling Bancorp Coverage Initiated at B. Riley
Restoration Hardware  Upgraded by ValuEngine to “Hold”
Restoration Hardware Upgraded by ValuEngine to “Hold”


© 2006-2019 Ticker Report